A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.
Advanced Solid Tumor|Metastatic Solid Tumor|Mature B-cell Non-Hodgkin Lymphoma
DRUG: ATG-101
AEs/SAEs, Toxicity will be graded according to the NCI CTCAE, Version 5.0., One year after last patient first dose|DLT (for Dose Escalation Phase only), The DLTs will be evaluated during Cycle 1 of treatment. Toxicity will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events. The DLTs for this study may include the following: Cytokine release syndrome, Hematologic toxicity, Non-hematologic toxicity., One year after last patient first dose
ORR, To evaluate preliminary anti tumor activity of ATG-101, One year after last patient first dose|DCR, To evaluate preliminary anti tumor activity of ATG-101, One year after last patient first dose|PFS, To evaluate preliminary anti tumor activity of ATG-101, One year after last patient first dose|OS, To evaluate preliminary anti tumor activity of ATG-101, One year after last patient first dose|The incidence of ADA and NAb, To evaluate the immunogenicity of ATG-101, One year after last patient first dose|Peak Plasma Concentration (Cmax), To evaluate the maximum plasma concentration (Cmax) of ATG-101 in Chinese patient population, One year after last patient first dose|Peak Plasma Concentration（Tmax）, To evaluate the time to reach Tmax of ATG-101 in Chinese patient population, One year after last patient first dose
This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas. Dose Escalation Phase: Approximately 40-50 subjects with a maximum number of 62; 1-20 subjects for enhanced PDx cohort. Dose Expansion Phase: Estimated between 2 and 5 cohorts, each of approximately 40-50 patients to be expanded.